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Summary
 
The B cell antigen receptor, composed of membrane immunoglobulin (Ig) sheathed by the
Ig
 
a
 
/Ig
 
b
 
 heterodimer plays a critical role in mediating B cell development and responses to an-
tigen. The cytoplasmic tails of Ig
 
a
 
 and Ig
 
b
 
 differ substantially but have been well conserved in
evolution. Transfection experiments have revealed that, while these tails share an esssential ty-
rosine-based activation motif (ITAM), they perform differently in some but not all assays and
have been proposed to recruit distinct downstream effectors. We have created transgenic
mouse lines expressing chimeric receptors comprising an IgM fused to the cytoplasmic domain
of each of the sheath polypeptides. IgM/
 
a
 
 and IgM/
 
b
 
 chimeras (but not an IgM/
 
b
 
 with mu-
tant ITAM) are each independently sufficient to mediate allelic exclusion, rescue B cell devel-
opment in gene-targeted Ig
 
m
 
2
 
 mice that lack endogenous antigen receptors, as well as signal
for B7 upregulation. While the (IgM/
 
a
 
) 
 
3 
 
(IgM/
 
b
 
) double-transgenic mouse revealed some-
what more efficient allelic exclusion, our data indicate that each of the sheath polypeptides is
sufficient to mediate many of the essential functions of the B cell antigen receptor, even if the
combination gives optimal activity.
 
T
 
he B cell antigen receptor (BCR)
 
1
 
, which is composed
of membrane immunoglobulin sheathed by the Ig
 
a
 
/
Ig
 
b
 
 heterodimer (CD79
 
a
 
/CD79
 
b
 
), mediates the response
of the B cell to antigen by initiating transmembrane signal-
ing and driving the internalization of antigen for presenta-
tion. The Ig
 
a
 
/Ig
 
b
 
 sheath is not only necessary for allowing
the surface transport of membrane IgM but is also critical
for mediating the signaling of the BCR and endocytic ac-
tivities (1, 2).
Various chimeric receptors have been used to dissect the
relative contributions of the Ig
 
a
 
 and Ig
 
b
 
 cytoplasmic do-
mains to BCR function. Because immunoreceptor ty-
rosine-based activation motifs (ITAMs) (3) present in both
sheath polypeptides are central to their signaling activity
(4–8), Ig
 
a
 
 and Ig
 
b
 
 may be functionally redundant. Indeed,
several transfection studies have failed to reveal significant
differences in the signaling activities of Ig
 
a
 
 and Ig
 
b
 
 (6, 7,
9). However, others have found that whereas chimeras
containing just the Ig
 
a
 
 tail could mediate transmembrane
signaling in B cell transfectants, analogous Ig
 
b
 
 chimeras
were impaired to variable extents (4, 10, 11, 12.). This, in
addition to the suggestion that the Ig
 
a
 
 and Ig
 
b
 
 cytoplasmic
domains bind different downstream effectors (13) and ex-
hibit differences in antigen-presenting activity (14), is con-
sistent with the two chains fulfilling distinct functions.
Experiments to ascertain whether there is a division of
function between the Ig
 
a
 
 and Ig
 
b
 
 cytoplasmic domains re-
veal that in vivo both IgM/
 
a
 
 and IgM/
 
b
 
 chimeras are able
to induce the pro-B to pre-B transition and mediate allelic
exclusion (8, 15). Here, we extend the transgenic analysis
to the later stages of B cell development, to ask about the
triggering of B cell maturation and activation.
 
Materials and Methods
 
DNA Constructs, Transfectants and Transgenic Mice.
 
Plasmids driv-
ing the expression of the hen egg lysozyme (HEL)–specific recep-
tors are based on pSV2gpt and pSV2neo. The 
 
k
 
 transcription
unit, in which the V
 
k
 
 segment of the mouse D1.3 mAb (16, 17)
is linked to rat C
 
k
 
, was assembled by exchanging the SacI–XhoI
 
b
 
-globin insert of L
 
k
 
-
 
b
 
G (18) for an analogous PCR-generated
SacI–XhoI fragment containing D1.3 V
 
k
 
. The heavy (H) chain
vectors derive from pSV–V
 
m
 
1 (19) but with the V
 
NP
 
 V
 
H
 
 segment
replaced by a PCR-generated PstI–BstEII D1.3 V
 
H
 
 segment. For
the chimeric 
 
m
 
 chains, the C
 
m
 
 region was replaced by C
 
m
 
/
 
b
 
 or
 
C
 
m
 
/
 
b
 
Y
 
®
 
L
 
 C
 
H
 
 regions (20) or C
 
m
 
/
 
a
 
 C
 
H
 
 regions (20a) (Fig. 1 
 
A
 
).
DNA was introduced into the mouse A20 B cell lymphoma by
electroporation and stably transfected clones selected in DMEM,
10% FCS, 50 
 
m
 
M 2-ME containing G418 and mycophenolic
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; BrdU,
5-bromo-2-deoxyuridine; H, heavy; HEL, hen egg lysozyme; ITAM,
immunoreceptor tyrosine-based activation motif; L, light.
  
1754
 
Ig
 
a
 
 and Ig
 
b
 
 in B Cell Antigen Receptor Function
acid. Transgenic mice were established by coinjection into zy-
gotes from (CBA/Ca 
 
3
 
 C57BL/6)F1 mice of an EcoRI frag-
ment containing the light (L) chain transcription unit together
with either a ClaI–XhoI (wild-type IgM) or ClaI–KpnI (chimeric
IgM) fragment for the H chain; founders were then bred with
(CBA/Ca 
 
3
 
 C57BL/6)F1s or crossed into a 
 
m
 
MT background
(21). For all four constructs, multiple founders were identified
that carried H or L chain transgenes. All chimeric H chain con-
structs were present in 10–20 copies. In the case of wild-type
HEL-specific IgM, two founders that had cointegrated the H and
L transcription units were studied and gave similarly effective al-
lelic exclusion, although only one of the two founders was bred
into a 
 
m
 
MT background. For the IgM/
 
b
 
 chimera, two founders
positive for both H and L expression were identified but only the
first founder was used in subsequent studies as the second founder
segregated the H and L transgenes on breeding. With IgM/
 
b
 
Y
 
®
 
L
 
and IgM/
 
a
 
, only a single positive H
 
1
 
L founder was obtained in
each case.
 
Flow Cytometry.
 
Analysis was performed on Becton Dickin-
son FACScan
 
Ò
 
 or FACScalibur
 
Ò
 
 using LYSYS II or CELLQuest
software. FITC-conjugated and biotinylated goat anti-IgM, and
PE-conjugated rat anti-IgD were from Southern Biotechnology
 
(Birmingham, AL); FITC–RA3-6B2 (rat anti-B220[CD45R]),
PE-conjugated B3B4 (rat anti-CD23), biotinylated 53-2.1 (rat
anti-Thy1.2[CD90]) and purified 7G6 (rat anti-CD21/35[CR2/1])
were from PharMingen (San Diego, CA); PE-conjugated RA3-
6B2 and RED670–streptavidin were from GIBCO BRL (Paisley,
UK); FITC–streptavidin was from Amersham (Amersham, UK);
and PE–streptavidin was from Jackson ImmunoResearch (West
Grove, PA). Cells making the E5.2 monoclonal anti-D1.3 idio-
type antibody (22) were a gift from R. Poljak. The flow cytomet-
ric analyses illustrated are representative of multiple individual an-
imals aged 2–4 mo old.
 
B Cell Activation.
 
Production of IL-2 from A20 transfectants
(10
 
5
 
 cells in 200 
 
m
 
l) cultured for 24 h in medium containing var-
ious concentrations of HEL was monitored by providing the cul-
ture supernatant to IL-2–dependent HT2 cells (2.5 
 
3
 
 10
 
4
 
 cells in
100 
 
m
 
l medium). The viability of the HT2 cells was determined
after 24 h as previously described (20) and the assay calibrated
with recombinant IL-2 standards.
To monitor proliferative responses, splenocytes that had been
depleted of erythrocytes by hypotonic lysis were cultured in trip-
licate aliquots (2 
 
3
 
 10
 
5
 
 in 200 
 
m
 
l) in RPMI, 10% FCS, 50 
 
m
 
M
2-ME in the presence of 1 
 
m
 
g/ml LPS (Sigma, Poole, UK) for 48 h
before pulsing with 0.5 
 
m
 
Ci [
 
3
 
H]thymidine for 15 h and scintilla-
tion counting.
To monitor CTLA4 binding, spleen cells depleted of erythro-
cytes were cultured (10
 
6
 
 cells/ml) in medium in the presence or
absence of 10 
 
m
 
g/ml F(ab
 
9
 
)
 
2
 
 goat anti–mouse IgM (Jackson Im-
munoResearch) for 24 h before staining with mCTLA4–H
 
g
 
1 fu-
sion protein (gift from P. Lane) and FITC-conjugated goat anti–
human IgG (Jackson ImmunoResearch).
 
BrdU Uptake.
 
Mice were given two intraperitoneal injections
4 h apart of 1 mg BrdU (5-bromo-2-deoxyuridine) (Sigma) in
PBS and the drinking water supplemented with 1 mg/ml BrdU
for 72 h following the protocol of Torres et al. (23). Spleens were
removed and, after staining for CD45R(B220) and either D1.3
idiotype or IgM, the cells were fixed and permeabilized with 70%
ethanol and 1% paraformaldehyde, 0.01% Tween-20 in PBS,
treated with DNaseI and stained with FITC-conjugated anti-
BrdU antibody (Becton Dickinson, San Jose, CA) for cytofluori-
metric analysis.
 
Results
 
The IgM/
 
a
 
 and IgM/
 
b
 
 but not IgM/
 
b
 
Y
 
®
 
L
 
 Chimeras Signal
in A20.
 
To discriminate between the functions of Ig
 
a
 
and Ig
 
b
 
 cytoplasmic domains, we constructed a set of plas-
mids encoding either wild-type or chimeric HEL-specific
receptors. The chimeras are composed of mouse 
 
m
 
 and rat
 
k
 
 Ig chains directly linked through a hydrophobic trans-
membrane segment to the cytoplasmic domains of either
Ig
 
a
 
, Ig
 
b
 
, or a mutated Ig
 
b
 
 whose ITAM tyrosines are sub-
stituted by leucines (IgM/
 
a
 
, IgM/
 
b
 
, or IgM/bY®L; Fig. 1
A). The transmembrane segment (which derives from the
H-2Kb gene) confers sheath-independent surface transport
(24) and the receptors do not show detectable association
with endogenous Iga or Igb chains (20).
The plasmids encoding the various receptors were trans-
fected into the A20 B cell lymphoma; the transfectants all
stained for IgM although there were some differences in
the brightness with the IgM/a chimera being the least well
transported to the cell surface (Fig. 1 B). The IgM/a and
Figure 1. Antigen induces IL-2 secretion from the A20 transfectants.
(A) Schematic representation of the transgene constructs and predicted
structures of the receptors (R, EcoRI; C, ClaI; P, PstI; Bs, BstEII; K,
KpnI; X, XhoI; S, SacI). (B) Flow cytometric analysis of transfected re-
ceptors in A20 by staining for surface IgM; unfilled histograms depict the
unstained controls. (C) Mean levels of IL-2 secreted by A20 transfectants
after incubation with hen egg lysozyme (HEL) for 24 h. Standard errors
were below 0.5 U/ml except where indicated.1755 Teh and Neuberger
IgM/b chimeras, as well as the wild-type IgM receptor,
were able to initiate signaling after antigen binding as
judged by the production of IL-2 from transfectants of the
A20 lymphoma (Fig. 1 C). However, the signaling activity
was abolished by mutation of the ITAM tyrosines in the
Igb cytoplasmic domain.
Receptor Expression in Transgenic Mice. The transcription
units encoding the various receptors were introduced into
the germline of transgenic mice. Cytofluorimetric analysis
of spleen cells with anti-D1.3 idiotype antibody (Fig. 2 A)
as well as with anti-rat k and labeled HEL (data not shown)
revealed that they were all expressed on the B cell surface,
although the IgM/a staining was weaker than that of the
other receptors. With the mice bearing the chimeric receptors,
the receptors were also expressed on some CD45R(B220)2
cells. These correspond to a subpopulation of T cells (Fig. 2
B), probably reflecting the expression pattern of the IgH
enhancer in transgenic mice (25). (The absence of surface
expression of the wild-type transgenic IgM receptor in this
subpopulation is consistent with the fact that wild-type
IgM, but not the IgM chimeras, requires endogenous Iga/
Igb for surface transport).
IgM/a and IgM/b but not IgM/bY®L Drive B Cell Develop-
ment. Signals transmitted through membrane Ig are required
for B cell development; mMT mice that carry a targeted
disruption of the m membrane exon are B cell deficient
(21). To see whether the individual Iga and Igb cytoplas-
mic domains of the IgM chimeras were sufficient to signal
for B cell maturation, the various transgenic lines were bred
into a homozygous mMT background. It was immediately
evident that the HEL-specific IgM BCR as well as the
IgM/a and IgM/b chimeras all had a significant effect on B
cell development; their presence led to a substantial (around
two log) increase in serum IgG levels as compared with
Figure 2. Expression of transgenes. (A) Flow cytometric analysis of spleens of transgenic mice. Cells were stained with FITC-conjugated anti-D1.3 id-
iotype and PE-conjugated anti-B220 and gated for propidium iodide exclusion. Numbers indicate percentage of splenocytes in each quadrant (Non-tg,
nontransgenic). (B) Transgene expression on T cells. Splenocytes were stained with FITC-conjugated anti-IgM, biotinylated anti-Thy1.2, and PE–
streptavidin; the profiles present the IgM staining of Thy1.21 gated cells.
Figure 3. The IgM, IgM/a and IgM/b, but not IgM/bY®L, transgenes reconstitute the splenic B cell pool in mMT mice. Splenocytes were stained
with FITC-conjugated anti-IgM and PE-conjugated anti-B220; the numbers denote the percentage of B2201 IgM1 cells within gated region and are
representative of multiple animals (WT 57 6 7% [n 5 8]; IgM 26 6 19% [n 5 4]; IgM/b 15 6 6% [n 5 5]; IgM/a 15 6 7% [n 5 8]). WT, wild-type
background; mMT, homozygous mMT background; Non-tg, nontransgenic.1756 Iga and Igb in B Cell Antigen Receptor Function
nontransgenic mMT controls. (Serum IgG is routinely de-
tected in reconstituted mMT mice and is presumably en-
coded by Ig-transgenic B cells that also carry productive
VHDJH integrations on an endogenous mMT allele that has
switched to a downstream isotype). The reconstitution of
peripheral B cell development was confirmed by cytofluo-
rimetric analysis of spleen cells: the presence of either the
IgM/a or the IgM/b chimera was sufficient to yield
splenic IgM1 B2201 cells with a functional ITAM being
essential for this activity (Fig. 3).
Phenotype of the Transgenic B Cells. Although these analy-
ses revealed that the IgM chimeras were able to drive the
Figure 4. Phenotypic analysis of the transgenic B cells. (A) The trans-
genic B cells proliferate poorly. After 48-h culture in the presence of LPS,
the splenocytes from wild-type, nontransgenic mice (WT, Non-tg), or
transgenic mice crossed into a mMT background were pulsed with
[3H]thymidine for 15 h before scintillation counting. Bars show mean
counts and standard errors were .10% of means. Counts after incubation
in medium alone were 1,000–1,500 cpm for nontransgenic and 200–300
cpm for transgenic cells. (B) Turnover of transgenic B cells. After uptake
of BrdU (5-bromo-2-deoxyuridine) for 72 h, spleen cells were stained
with PE-conjugated anti-B220 and biotinylated anti-D1.3 idiotype or
anti-IgM (nontransgenic only) and RED670–streptavidin. After fixation
and permeabilization, cells were stained with a FITC-conjugated anti-
BrdU antibody. The analyses (10,000 gated cells) are presented for cells
that have been gated as B2201. Whereas 10–20% of the IgM1 cells in
nontransgenic mice had incorporated BrdU, the figure increased to 40–
50% of the D1.3 idiotype1 cells in the transgenic lines. (C) Splenic B cells
from IgM and IgM/b express lower levels of mature B cell markers
CD21/35 and CD23. Histograms show splenic B cells from transgenic
mice crossed into a mMT background overlaid on nontransgenic controls
(shaded). For CD21/35 expression, splenocytes were stained with FITC–
anti-IgM, PE–anti-B220, and biotinylated anti-CD21/35 (revealed by
RED670–streptavidin), gating by lymphocyte scatter and B2201 IgM1.
For CD23 expression, cells were stained with FITC–anti-B220 and PE–
anti-CD23, gating by scatter and B2201.
maturation of a splenic B cell population, we found that
the reconstituted B cells proliferated extremely poorly on
in vitro culture with LPS (Fig. 4 A). Indeed, compared
with normal controls, the transgenic B cells exhibited a
two- to fivefold increase in cell death during a 24-h in vitro
culture. The diminished proliferative response is not unique
to the IgM chimeras: it is also evident in mice transgenic
for the wild-type anti-HEL IgM (Fig. 4 A). An altered
turnover of the transgenic B cells is also apparent in vivo:
BrdU labeling revealed that animals carrying the transgenic
receptors had an increased proportion of rapidly turning
over splenic B cells (Fig. 4 B). With regard to surface mark-
ers, splenic B cells from mice transgenic for both the wild-
type IgM and the IgM chimeras revealed a shift to lower
expression of the mature B cell markers, CD21/35 and
CD23 (Fig. 4 C) as compared with normal mice, though
CD22 expression was unaffected. Thus, in view of their di-
minished proliferative response, increased in vivo turnover
and decreased expression of CD21/35 and CD23, it is evi-
dent that the splenic B cells whose development is driven
by the transgenic anti-HEL receptors do not show the same
distribution of maturational development as splenic B cells in
normal mice. However, this is an effect of all the anti-HEL
transgenes and does not indicate compromised signaling by
either of the individual IgM chimeras.
Upregulation of B7 by the IgM/a and IgM/b Chimeras.
To monitor signaling by the IgM chimeras in the trans-
genic B cells, we sought to measure the proliferative re-
sponses to anti-IgM and IL-4. However, as with LPS, the
responses were very poor; therefore, we used upregulation
of the B7 costimulatory molecules as our readout. Splenic
B cells from the transgenic mice were cultured for 24 h
with anti-IgM and upregulation of B7 was judged by stain-
ing with a CTLA4–Ig fusion protein (Fig. 5 A). Triggering
the receptors with HEL or anti-D1.3 idiotype antibody
gave analogous results but additionally revealed that the
IgM/bY®L receptor was signaling defective (data not shown).
The IgM/a and IgM/b Chimeras Give Partial Allelic Exclu-
sion but the Combination is Optimal. The ability to mediate
the feedback regulation of endogenous Ig gene rearrange-
ment (allelic exclusion) provided another parameter for
comparing the signaling ability of the different receptors.
Allelic exclusion in the transgenic mice was readily moni-
tored by determining the proportion of D1.3 idiotype1 B
cells that coexpress IgD and gave similar conclusions to
staining with anti-m allotype antibodies. It will be seen
(Fig. 5 B) that the exclusion mediated by the wild-type
HEL receptor is significantly greater than that mediated by
the IgM/a and IgM/b chimeras. The IgM/bY®L receptor
is ineffective in exclusion with all D1.3 idiotype1 B cells
coexpressing an endogenous rearrangement. We crossed
the IgM/a and IgM/b chimeras to see whether coexpres-
sion of the two receptors yielded more complete exclusion.
The double-transgenic mice exhibited greatly decreased
expression of endogenous Ig gene rearrangements (Fig. 5
B) despite the fact that there was no significant increase in
the abundance of transgenic IgM on the B cell surface (see
Fig. 2 A).1757 Teh and Neuberger
Discussion
The results show that both the IgM/a and IgM/b chi-
meras can broadly perform many of the major in vivo func-
tions of the complete BCR. Furthermore, the ability to
drive the maturation and activation of peripheral B cells is
dependent upon the ITAM; this parallels previous findings
on pre-B cell development (8, 15).
Transfection experiments using cell lines have revealed
that both Iga and Igb are needed for surface transport of
membrane Ig (26, 27). Thus, mice carrying targeted dis-
ruptions of Igb cannot express surface Ig and are B cell de-
ficient (28). In contrast, both the IgM/a and IgM/b chi-
meras described here allow extensive B cell maturation
because, by virtue of their mutant transmembrane se-
quences, these chimeras can be transported to the B cell
surface without an attendant Iga/Igb sheath. The IgM/b
chimera performs slightly better than the IgM/a chimera
in several of the assays but this may simply reflect the more
efficient surface transport of the IgM/b chimera.
Therefore, our results so far do not lend significant sup-
port to the idea that Iga and Igb cytoplasmic domains per-
form distinct autonomous functions within the context of
the intact BCR. Nevertheless, it is clear that the chimeras are
not as effective as the complete BCR. Thus, the (IgM/a) 3
(IgM/b) double transgenic mouse is considerably more effi-
cient than its single transgenic parents in effecting allelic
exclusion of endogenous Ig gene rearrangement. This is
consistent with cell line transfection experiments indicating
cooperativity between the two cytoplasmic domains with
the heterodimer giving a stronger signal than the compo-
nent homodimers (29). Indeed, the structural conformation
of the heterodimer could differ substantially from that of
the homodimers and this could lead to differences in the
kinetics of phosphorylation or efficacy of effector protein
(e.g., Syk) recruitment, as well as in the sensitivity to anti-
gen binding.
However, although the chimeric HEL-specific receptors
do not perform as well as the wild-type IgM BCR in driv-
ing the reconstitution of a splenic B cell compartment in
mMT mice, the difference is relatively small and the im-
paired B cell maturation is certainly not nearly as dramatic
as that observed by Torres et al. (23) in mice carrying a tar-
geted disruption of the mb-1 gene that leads to the synthesis
of a BCR with a truncated Iga tail. The different perfor-
mance of the various compromised BCRs in driving pre-B
and B cell development could well be accounted for by a
requirement for differing qualities of signal at the various
maturational checkpoints. It will obviously be interesting
to correlate the differentiative potential of the various mu-
tant BCRs with their biochemical signaling activities.
Figure 5. In vitro activation
and allelic exclusion. (A) Upreg-
ulation of CTLA4 binding fol-
lowing a 24-h culture with anti-
IgM or medium alone (Ctrl).
Cultured splenocytes from trans-
genic mice in a mMT back-
ground (or wild-type nontrans-
genic controls, WT, Non-tg)
were stained with PE–anti-B220
and an mCTLA4–Hg1 fusion
protein, which was visualized
with FITC–anti-human IgG.
The profiles were gated for
B2201 cells that excluded pro-
pidium iodide. (B) Exclusion of
endogenous IgD. Splenocytes
were stained with FITC–anti-
B220, PE–anti-IgD, and biotin-
ylated anti-D1.3 plus RED670–
streptavidin. Cells were gated for
B2201 and numbers denote per-
centage of splenic B cells within
each quadrant.
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